RETRACTED: A Genomic Strategy to Refine Prognosis in Early-Stage Non–Small-Cell Lung Cancer

Authors:
  • SMSayan Mukherjee
    Sayan Mukherjee
  • RPRebecca Petersen
    Rebecca Petersen
  • HDHolly K. Dressman
    Holly K. Dressman
  • ABAndrea Bild
    Andrea Bild
  • JKJason Koontz
    Jason Koontz
  • RKRobert Kratzke
    Robert Kratzke
  • MWMark A. Watson
    Mark A. Watson
  • GGGeoffrey S. Ginsburg
    Geoffrey S. Ginsburg
  • MWMike West
    Mike West
  • DHDavid H. Jr. Harpole
    David H. Jr. Harpole

Abstract
Clinical trials have indicated a benefit of adjuvant chemotherapy for patients with stage IB, II, or IIIA — but not stage IA — non–small-cell lung cancer (NSCLC). This classification scheme is probably an imprecise predictor of the prognosis of an individual patient. Indeed, approximately 25 percent of patients with stage IA disease have a recurrence after surgery, suggesting the need to identify patients in this subgroup for more effective therapy.

This publication has 32 references indexed in Scilit: